Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Second-Line Therapy for Metastatic Pancreatic Adenocarcinoma

Grants and Contracts Details

StatusActive
Effective start/end date12/15/214/29/26

Funding

  • Exelixis Inc.: $166,708.00